IP Library Granted Patent US 10,687,975
Granted Patent B2
US 10,687,975 · App. 15/983,250 · Granted Jun 23, 2020

Method and system to facilitate the growth of desired bacteria in a human's mouth

Inventors: Joseph E. Kovarik (Englewood, CO); Katherine Rose Kovarik (Englewood, CO)
A61F5/566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,687,975
App. No.
15/983,250
Granted
Jun 23, 2020
Kind
B2
Abstract

A method and system for addressing the avoidance of migraines, cluster headaches and dizziness by adjusting an individual's microbiome, and in particular, to the provision of beneficial oral and gut microbes at particular times to enhance a person's oral health, including through the use of oral strips that adhere to surfaces in the oral cavity and that include at least one of xylitol, Lachnospira, Veillonella, Faecalibacterium and/or Rothia bacteria, including bacteria transformed via a CR/SPR system.

Claims (24)

1. A method to facilitate the growth of desired bacteria in a human's mouth by using a buccal bioadhesive strip, comprising:

providing to an individual in need thereof a buccal bioadhesive strip, said strip having a first and second side, said first side having a surface comprising a pattern defined by a plurality of spaced apart features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 micrometers in at least a portion of said surface, the second side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person's mouth, wherein said strip includes at least one encapsulated feature containing at least one bacteria that has one of a pathogenic or toxic element excised using a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system.

2. The method as set forth in claim 1 , wherein said at least one bacteria has a toxic element excised using a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) system.

3. The method as set forth in claim 1 , wherein said at least one bacteria is transformed by a CRISPR-Cas system to render said at least one bacteria sensitized to an antibiotic.

4. The method as set forth in claim 1 , wherein said at least one bacteria is modified by employment of a CRISPR-Cas or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to reduce the expression of an endogenous pathogenic protein.

5. The method as set forth in claim 1 , wherein said at least one bacteria is modified by employment of a CRISPR-Cas or Cpf1 system to remove a virulence factor selected from the group consisting of the production of gelatinase and hemolysin, and adherence to caco-2 and hep-2 cells.

6. A method to facilitate the growth of desired bacteria in a human's mouth by using a buccal bioadhesive strip, comprising:

providing to an individual in need thereof a buccal bioadhesive strip, said strip having a first and second side, said first side having a surface comprising a pattern defined by a plurality of spaced apart features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 micrometers in at least a portion of said surface, the second side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person's mouth, wherein said strip includes at least one bacteria, wherein said at least one bacteria is modified by employment of a CRISPR-Cas or Cpf1 system to remove a virulence factor selected from the group consisting of the production of gelatinase and hemolysin, and adherence to caco-2 and hep-2 cells.

7. The method as set forth in claim 6 , wherein said at least one bacteria is modified by employment of a CRISPR-Cas or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to reduce the expression of an endogenous pathogenic protein.

8. The method as set forth in claim 6 , wherein said at least one bacteria is transformed by a CRISPR-Cas system to render said bacteria sensitized to an antibiotic.

9. The method as set forth in claim 1 , wherein said at least one bacteria has a pathogenic element excised using a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) system.

10. A method to facilitate the growth of desired bacteria in a human's mouth by using a buccal bioadhesive strip, comprising:

providing to an individual in need thereof a buccal bioadhesive strip, said strip having a first and second side, said first side having a surface comprising a pattern defined by a plurality of spaced apart features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 micrometers in at least a portion of said surface, the second side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person's mouth, wherein said strip includes at least one encapsulated feature containing at least one bacteria transformed by a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to render said bacteria sensitized to an antibiotic.

11. The method as set forth in claim 10 , wherein said at least one bacteria has one of a pathogenic or toxic element excised using a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system.

12. The method as set forth in claim 10 , wherein said at least one bacteria is modified by employment of a CRISPR-Cas or a Cpf1 system to reduce the expression of an endogenous pathogenic protein.

13. The method as set forth in claim 10 , wherein said at least one bacteria is modified by employment of a CRISPR-Cas or Cpf1 system to remove a virulence factor selected from the group consisting of the production of gelatinase and hemolysin, and adherence to caco-2 and hep-2 cells.

14. The method as set forth in claim 10 , wherein said strip is dissolvable in a person's mouth.

15. The method as set forth in claim 10 , wherein said strip includes xylitol.

16. The method as set forth in claim 10 , wherein said strip includes at least 200 mg of xylitol.

17. A method to facilitate the growth of desired bacteria in a human's mouth using a buccal bioadhesive strip, comprising: providing a strip that has a first and second side, the first side having a bioadhesive that is adapted to binds to a mucosal membrane for at least 1 hour while inside a person's mouth, the second side having a specially textured surface that has anti-microbial characteristic derived from its surface topography, said topography such that it resists bioadhesion of undesired bacteria that are typically present in a human's mouth, said second side having a pattern defined by a plurality of spaced apart features attached to or projected into a base surface, said plurality of features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 .mu.m in at least a portion of said coating layer, said coating layer resisting bioadhesion as compared to said base surface, wherein the strip has first and second sides and the first side has adhesive material associated therewith and the second side does not, and comprises bioluminescent material to facilitate a user's ability to view when viewing in a mirror, the correct placement of the strips in one's throat, said bioluminescent material comprising one of luciferin, luciferase and aequorin wherein said strip has compounds residing thereon to facilitate the growth of desired bacteria beneficial to a person's health.

18. The method of claim 17 , wherein the film has first and second sides and the first side has adhesive material associated therewith and the second side does not.

19. The method of claim 17 , wherein said strip includes at least one polymer selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethylcellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.

20. The method of claim 17 , wherein said strip comprises bioluminescent material to facilitate a user's ability to view when viewing in a mirror, the correct placement of the strips in one's throat, said bioluminescent material comprising one of luciferin, luciferase and aequorin.

21. The method of claim 17 , wherein said strip further comprises breath freshening components.

Assignments (3)
SECURITY INTEREST Recorded Jul 21, 2026
From: SEED HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS LENDER
Reel/Frame 076028/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: KOVARIK, JOE
To: SEED HEALTH, INC.
Reel/Frame 059690/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2021
From: KOVARIK, JOSEPH E
To: KOVARIK, JOSEPH E.
Reel/Frame 057819/0661 →
Continuity (25)
Continuation In Part 15384716 · Dec 20, 2016
Continuation In Part 14752192 · Jun 26, 2015
Continuation In Part 14225503 · Mar 26, 2014
Continuation 13367052 · Feb 6, 2012
Continuation In Part 15270034 · Sep 20, 2016
Continuation In Part 14954074 · Nov 30, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation In Part 15228454 · Aug 4, 2016
Continuation In Part 14611458 · Feb 2, 2015
Continuation In Part 14502097 · Sep 30, 2014
Continuation 14307651 · Jun 18, 2014
Continuation In Part 14079054 · Nov 13, 2013
Continuation 13425913 · Mar 21, 2012
Provisional Application 62387405 · Dec 24, 2015
Provisional Application 61439652 · Feb 4, 2011
Provisional Application 61556023 · Nov 4, 2011
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62014855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Provisional Application 62387404 · Dec 24, 2015
Provisional Application 62274550 · Jan 4, 2016
Provisional Application 62275341 · Jan 6, 2016
Provisional Application 61467767 · Mar 25, 2011
Related Publication 20180263808A1 · Sep 20, 2018
Cited By (7)
US 12,246,043 US 12,257,272 US 12,279,989 US 12,318,411 US 12,318,414 US 12,357,662 US 12,533,312